T173. POLYGENETIC RISK SCORES FOR MAJOR PSYCHIATRIC DISORDERS AMONG SCHIZOPHRENIA PATIENTS, THEIR FIRST-DEGREE RELATIVES AND HEALTHY SUBJECTS
Authors: Ohi Kazutaka , Nishizawa Daisuke , Shimada Takamitsu , Kataoka Yuzuru , Hasegawa Junko , Shioiri Toshiki , Kawasaki Yasuhiro , Hashimoto Ryota , Ikeda Kazutaka 
Published: May 2020

Background

The genetic etiology of schizophrenia (SCZ) overlaps with that of other major psychiatric disorders in samples of European ancestry. On the other hand, these major psychiatric disorders are distinct diagnoses that have disorder-specific genetic factors. Recently, the bipolar disorder (BIP) and SCZ Working Group of the PGC identified two genome-wide significant loci differentiating the two disorders in individuals of European descent. We hypothesized that genetic variants differentiating SCZ from BIP in Europeans as well as genetic variants related to psychiatric disorders in Europeans would overlap with genetic risk variants in Japanese SCZ patients and unaffected first-degree relatives (FRs), i.e., individuals at high risk of developing SCZ. The present study investigated transethnic polygenetic features shared between Japanese SCZ or their unaffected FRs and European patients with major psychiatric disorders by conducting polygenic risk score (PRS) analyses.

Methods

To calculate PRSs for five psychiatric disorders [SCZ, BIP, major depressive disorder (MDD), autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD)] and PRSs differentiating SCZ from BIP, we utilized large-scale European genome-wide association study (GWAS) datasets as discovery samples. PRSs derived from these GWASs were calculated for 335 Japanese target subjects [131 SCZ patients, 57 of their unaffected FRs and 147 healthy controls (HCs)]. We took these PRSs based on GWASs of European psychiatric disorders (SCZ, BIP, SCZ vs BIP, MDD, ASD and ADHD) and investigated their effect on risk in Japanese SCZ patients [(i) SCZ vs FRs vs HCs, (ii) SCZ vs HCs and (iii) SCZ vs FRs] or unaffected FRs [(iv) FRs vs HCs] by PRS analyses.

Results

The PRSs obtained from European SCZ samples were significantly higher in Japanese patients with SCZ than in HCs [(i) SCZ vs FRs vs HCs, a maximum at PT≤1.0: adjusted R2=0.028, p=1.30×10–3; (ii) SCZ vs HCs, a maximum at PT≤1.0: Nagelkerke’s R2=0.049, p=1.66×10–3]. In addition, the PRSs related to European BIP were nominally higher in Japanese patients with SCZ than in HCs [(i) SCZ vs FRs vs HCs, a maximum at PT≤0.5: adjusted R2=0.016, p=0.012; (ii) SCZ vs HCs, a maximum at PT≤0.5: Nagelkerke’s R2=0.029, p=0.015]. Furthermore, PRSs differentiating SCZ patients from European BIP patients were marginally higher in Japanese SCZ patients than in HCs [(i) SCZ vs FRs vs HCs, a maximum at PT≤0.05: adjusted R2=0.010, p=0.043; (ii) SCZ vs HCs, a maximum at PT≤0.05: Nagelkerke’s R2=0.020, p=0.046]. Interestingly, the PRSs obtained from European ASD were marginally lower in Japanese FRs compared with HCs [(iv) FRs vs HCs, a maximum at PT≤0.01: Nagelkerke’s R2=0.045, p=0.013] and patients with SCZ [(iii) SCZ vs FRs, a maximum at PT≤0.2: Nagelkerke’s R2=0.023, p=0.084]. As childhood-onset patients with SCZ have showed higher PRSs for both SCZ and ASD than their unaffected siblings, we further investigated the correlation between age at onset and PRSs for both SCZ and ASD in our SCZ samples. Lower age at onset of SCZ was significantly associated with higher PRSs for ASD (PT≤0.05: beta=-0.20, p=7.13×10–3) but not PRSs for SCZ (p&gt;0.05).

Discussion

These findings suggest that polygenic factors related to European SCZ and BIP and the polygenic components differentiating SCZ from BIP can transethnically contribute to SCZ risk in Japanese people. Furthermore, we suggest that reduced levels of an ASD-related genetic factor in unaffected FRs may help protect against SCZ development.